 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234 |
- |||| Trial completion: Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy (clinicaltrials.gov) - Apr 15, 2014
P2, N=60, Completed, Sponsor: ThromboGenics
Recruiting --> Completed
- ||||| Jetrea (ocriplasmin) / Oxurion
Enrollment closed, P3 data: A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion (clinicaltrials.gov) - Mar 27, 2014
P3, N=168, Active, not recruiting, Sponsor: Alcon Research
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Enrollment change: MIVI-8: Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion (clinicaltrials.gov) - Mar 18, 2014
P2, N=17, Completed, Sponsor: ThromboGenics
Recruiting --> Active, not recruiting N=30 --> 17
- ||||| Jetrea (ocriplasmin) / Oxurion
New P4 trial: Assessment of Patients Treated With JETREA® for Vitreomacular Traction (clinicaltrials.gov) - Jan 12, 2014
P4, N=400, Recruiting, Sponsor: Alcon Research
- ||| Enrollment change: A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) (clinicaltrials.gov) - Jul 3, 2013
P2, N=60, Completed, Sponsor: ThromboGenics
N=30 --> 17 N=90 --> 60
- |||||||||| Jetrea (ocriplasmin) / Oxurion
New P3 trial, P3 data: A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion (clinicaltrials.gov) - Jun 26, 2013
P3, N=168, Active, not recruiting, Sponsor: Alcon Research
- |||| Trial completion: MIVI-5: Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion (clinicaltrials.gov) - Jun 5, 2013
P2, N=100, Completed, Sponsor: ThromboGenics
N=90 --> 60 Active, not recruiting --> Completed
- | Trial completion: Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy (clinicaltrials.gov) - Jan 21, 2013
P2, N=24, Completed, Sponsor: ThromboGenics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment closed: Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (clinicaltrials.gov) - Nov 14, 2012
P2, N=220, Active, not recruiting, Sponsor: ThromboGenics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Jetrea (ocriplasmin) / Oxurion
Trial termination: MIME: Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema (clinicaltrials.gov) - Aug 13, 2012
P1/2, N=2, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Completed --> Terminated; Lack of enrollment.
- Jetrea (ocriplasmin) / Oxurion
Trial initiation date: MIME: Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema (clinicaltrials.gov) - Aug 13, 2012
P1/2, N=2, Terminated, Sponsor: National Institutes of Health Clinical Center (CC)
Completed --> Terminated; Lack of enrollment. Initiation date: Aug 2010 --> Jan 2011
- | Enrollment change: Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy (clinicaltrials.gov) - Apr 4, 2012
P2, N=24, Completed, Sponsor: ThromboGenics
Initiation date: Aug 2010 --> Jan 2011 N=30 --> 24
- Enrollment change: Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies (clinicaltrials.gov) - Nov 14, 2011
P=N/A, N=24, Completed, Sponsor: ThromboGenics
N=30 --> 24 N=44 --> 24
- | Trial completion: Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies (clinicaltrials.gov) - Nov 14, 2011
P=N/A, N=24, Completed, Sponsor: ThromboGenics
N=44 --> 24 Recruiting --> Completed
- ||||| New P2 trial: Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (clinicaltrials.gov) - Sep 5, 2011
P2, N=220, Active, not recruiting, Sponsor: ThromboGenics